Gas Natural Inc (NYSEMKT:EGAS) belongs to Utilities sector and Gas Utilities industry. EGAS stock opened its current trade at $12.75 and now floating in a range of $12.44 to $12.85, trading at $12.60. EGAS stock gain 64.06% in total of its share price. EGAS stock’s 52-week range is $6.50 – $12.85. Gas Natural Inc. (NYSE MKT: EGAS) (“Gas Natural” or the “Company”), a holding company operating local natural gas utilities serving about 68,000 customers in four states, recently declared the signing of a definitive merger agreement with an energy infrastructure investment fund sponsored by First Reserve, a leading global private equity and infrastructure investment firm focused exclusively on energy.
Under the terms of the agreement, First Reserve has agreed to acquire all of the outstanding shares of Gas Natural common stock for $13.10 per share, for a total enterprise value of about $196 million. The purchase price represents an approximate premium of 39% over Gas Natural’s 52-week high.
Gregory J. Osborne, Gas Natural’s President and Chief Executive Officer, commented, “This agreement validates the strength of our franchise, provides great opportunity for our employees, ensures continuity of administration and processes for our regulators, and rewards our shareholders for their commitment. Equally as important, there will not be any change to our organization or operations. In partnering with First Reserve, a long-term shareholder excited about the opportunity for continued investment, we maintain our strong dedication to providing safe, clean, reliable and affordable energy to our customers and to expanding the number of customers that have access to our responsive, quality service.”
Macrocure Ltd (NASDAQ:MCUR) gain 34.27% and trading in the current trading session at $1.92. MCUR stock’s price is now -54.70% down from its 52-week high and 157.32% up from its 52-week low. Beta factor is used to measure the volatility of the stock. The stock remained 5.56% volatile for the week and 6.41% for the month. Macrocure Ltd., a biotechnology company, focuses on developing, manufacturing, and commercializing novel cell therapy products for the treatment of chronic and other hard-to-heal wounds in Israel. Macrocure Ltd. was founded in 2008 and is headquartered in Petach Tikva, Israel.